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Abstract
Osteogenesis imperfecta (OI) is an uncommon genetic bone disease
associated with brittle bones and fractures in children and adults. Although OI is
most commonly associated with mutations of the genes for type I collagen,
many other genes (some associated with type I collagen processing) have now
been identified. The genetics of OI and advances in our understanding of the
biomechanical properties of OI bone are reviewed in this article. Treatment
includes physiotherapy, fall prevention, and sometimes orthopedic procedures.
In this brief review, we will also discuss current understanding of pharmacologic
therapies for treatment of OI.
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Introduction
Osteogenesis imperfecta (OI) is an unusual heritable disease that 
occurs in about 1 in 10,000 to 20,000 live births1. The major clinical 
manifestation is skeletal fragility. Skeletal deformity, joint laxity, 
and scoliosis may be present2. Other extraskeletal manifestations 
include hearing loss, dentinogenesis imperfecta, blue/gray sclerae, 
hypercalciuria, aortic root dilatation, and neurologic conditions 
such as macrocephaly, hydrocephalus, and basilar invagination1–5. 
The phenotype is variable, ranging from osteoporosis present-
ing in adulthood to lethality in children3. Even adults with “mild” 
OI may have significant musculoskeletal symptoms, including 
arthritis, fractures, back pain, scoliosis, and tendon ruptures6.
About 90% of patients have mutations in type I collagen genes 
(COL1A1 and COL1A2)3; however, many other genes have now 
been described. Some of the genes encode proteins related to type I 
collagen (for example, enzymes that modify type I collagen, chap-
erone proteins, and signaling proteins). In 1979, Sillence et al. 
proposed a classification system for OI with four types based 
on severity: type I mild non-deforming, type II perinatal lethal, 
type III severely deforming, and type IV moderately deforming7. 
This classification has been expanded as new genes were discov-
ered. Phenotypic classification (types I to V with multiple genes 
included in some of the types) has been proposed5. Alternatively, 
classification by genetics has been proposed (see Table 1), which 
was created through modifications of references8–10.
There have been recent advances in the understanding of the 
structure and mechanical properties of bone in children with OI. 
These advances may lead to improved finite element (FE) models 
that help predict fracture risk of specific activities and help plan 
physiotherapy.
In addition to physiotherapy and orthopedic surgery when needed, 
intravenous bisphosphonates have been used extensively in mod-
erate to severe OI in childhood. Less is known about pharmaco-
logic treatment in adults. Anabolic therapy with PTH 1-34 has been 
studied in adults with OI. Future therapies may include antibodies 
to sclerostin, transforming growth factor beta (TGFβ) antagonism, 
gene therapy, and cell-based therapies.
Genes and classification
OI is most commonly caused by mutations in type I collagen. Type 
I collagen is a rod-like structure formed from a trimer of 2 COL1A1 
and 1 COL1A2 subunits3, which requires post-translational modi-
fication. Many of the other rare forms of OI are due to defects in 
Table 1. Classification of osteogenesis imperfecta.
Type Inheritance Gene Protein Defect Phenotype
I AD COLA1/COLA2 α1(1) collagen Collagen quantity Mild, non-deforming
II AD COLA1/COLA2 α1(1)/α2(1) collagen Collagen structure Perinatal lethal
III AD COLA1/COLA2 α1(1)/α2(1) collagen Collagen structure Progressively deforming
IV AD COLA1/COLA2 α1(1)/α2(1) collagen Collagen structure Moderately deforming
V AD IFITM5 BRIL Matrix mineralization Moderate, distinct 
histology
VI AR SERPINF1 PEDF Moderate to severe, 
distinct histology
VII AR CRTAP CRTAP Prolyl 3 hydroxylation Severe to lethal
VIII AR LEPRE1 P3H1 Prolyl 3 hydroxylation Severe to lethal
IX AR PPIB CyPB Prolyl 3 hydroxylation Moderate to lethal
X AR SERPINH1 HSP47 Collagen chaperoning Severe
XI AR FKBP10 FKBP65 Telopeptide hydroxylation Progressively deforming 
(Bruck syndrome)
XII AR SP7 SP7/osterix Osteoblast development Moderate
XIII AR BMP1 BMP1/mTLD Collagen processing Severe, high bone mass
XIV AR TMEM38B TRIC-B Cation channel defect Moderate to severe
XV AR WNT1 WNT1 Variable
XV AD WNT1 WNT1 Early-onset osteoporosis
Others
AR CREB3L1 Oasis COL1A1 transcription Progressively deforming
XL PLS3 Plastin Osteocyte defect Mild
AR PLOD2 Lysyl hydroxylase 2 Collagen telopeptide 
hydroxylation
Progressively deforming
AD, autosomal dominant; AR, autosomal recessive; XL, x-linked.
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proteins involved in cross-linking, hydroxylation, and mineraliza-
tion of type I collagen.
Mutations of CRTAP, which encodes cartilage-associated protein, 
have been shown to cause recessive OI11–14. Mutations of LEPRE1, 
which encodes prolyl 3 hydroxylase14–16, and PPIB (protein cyclo-
phylin B)17–19 also cause recessive OI. The proteins described above 
form a complex that modifies specific prolines in the collagen and 
these mutations result in moderate to lethal OI.
SERPINH1 mutations cause severe recessive OI20. The protein 
affected in SERPINH1 mutations, HSP47, is a collagen chaperone 
protein8. FKBP10 mutations cause recessive OI (progressively 
deforming)21. This gene encodes the protein FKBP65, which 
appears to be needed for hydroxylation of collagen telopetide 
lysine22. Both HSP47 and FKBP65 are needed for the proper fold-
ing of the collagen triple helix. Furthermore, Bruck syndrome 
(OI and congenital contractures) can be caused by homozygous 
mutations on FKPB1023, and Kuskokwim syndrome (congenital 
contractures with mild skeletal problems seen in Yup’ik people in 
Alaska) is caused by FKBP10 mutations24. PLOD2 mutations also 
cause recessive OI25. PLOD-2 encodes lysyl hydroxylase 2, which 
hydroxylates collagen telopeptide lysine. Bruck syndrome can also 
be caused by homozygous mutations of PLOD225.
BMP1 (bone morphogenetic protein 1) mutations also cause reces-
sive OI26,27. The protein, BMP1, is a protease that cleaves the 
c-propeptide of type I collagen26,27 but also has other substrates. 
SP7 mutations cause recessive OI28. SP7 encodes the protein 
osterix, which may be needed for osteoblast differentiation10. WNT1 
mutations29–31 have been reported in early-onset osteoporosis (domi-
nant) and OI (recessive). The protein, WNT1, may be important in 
the beta catenin system, which stimulates bone formation29–31.
TMEM38B mutations have been reported in recessive OI32. This 
gene encodes TRIC-B, which may be important in intracellular cal-
cium signaling. Defective TRIC-B may cause bone disease through 
defective calcium signaling in bone cells10. CREB3L1 mutations 
cause recessive OI33. CREB3L1 encodes the protein OASIS, which 
may activate transcription of COL1A134. PLS3 (plastin 3) muta-
tions have been reported in x-linked osteoporosis35–37. Plastin 3 is 
expressed in osteocyte dendrites and may be important in mechano-
sensing35. Bone biopsies from patients with PLS3 mutations have 
shown cortical and trabecular osteoporosis with normal to low bone 
formation rates36,37. There is no mineralization defect36,37.
Mutations in IFITM5, a bone-restricted IFITM-like protein (BRIL) 
(dominant) cause type V OI38–42. These patients have prominent cal-
lus formation and ossification of the forearm interosseous mem-
brane38–42. They also have mesh-like lamellation on bone biopsy as 
well as a mineralization defect38–42. There appear to be substantial 
differences in phenotypic presentation even with similar muta-
tions40–42. Type VI OI is caused by mutations in SERPINF1 (protein 
PEDF)43,44. Children with type VI OI have elevated alkaline phos-
phatase, and bone biopsy reveals fish-scale pattern under polarized 
light as well as broad bands of unmineralized osteoid43,44. Interest-
ingly, some patients with BRIL mutations have phenotypic type VI 
OI (rather than type V)45. BRIL and PEDF are related, and it appears 
that mutations causing gain-of-function of BRIL cause OI type V 
and that those causing loss-of-function of BRIL look phenotypically 
like OI type VI46.
Structure and mechanical properties of bones in 
osteogenesis imperfecta
From a mechanical perspective, increased fracture risk in indi-
viduals with OI could stem from a combination of reduced bone 
mass, decreased bone material quality, and, in some individuals, the 
presence of bone deformity.
Bone mass
Low bone mass is a clinical characteristic of OI, and individuals 
with this disorder tend to have markedly reduced areal bone min-
eral density (BMD)47–49. This reduced bone mass can be the con-
sequence of decreased bone size or decreased volumetric BMD or 
both49,50. Studies of iliac crest biopsies have revealed lower bone 
tissue quantity in children with moderate and severe OI, including 
reduced bone volume fraction, and decreased trabecular and corti-
cal thicknesses51–53. Decreased bone volume, though less marked, 
was also noted in some children with mild OI51,52.
In cortical bone specimens from the long bone shafts of children 
with OI, “atypical, flattened, and large resorption lacunae”54 and 
abnormally elevated porosity have been observed54–57. For exam-
ple, an average intracortical vascular porosity of 21% was found 
in bone shaft osteotomies from children with OI by synchrotron 
radiation micro-computed tomography55,57; the corresponding value 
in normal pediatric bones was 3%57. From a structural perspec-
tive, reduced bone mass can lead to increased stresses within the 
bone as a result of a smaller area of bone tissue present to sup-
port physiological loads. For this reason, low bone mass is likely a 
considerable contributor to bone fragility in OI.
Bone material quality
In addition to the structural deficiency (low bone mass), mechanical 
quality of the bone material in OI is reduced. The genetic defects 
causing OI affect type I collagen, the main organic component of 
bone. As discussed earlier, most forms of OI (types I to IV) are 
attributed to insufficient collagen production or amino acid substi-
tution defects within the collagen molecules or both58–63, and less 
common recessive forms have been associated with abnormalities 
in other proteins that interact with type I collagen9,64. Since type I 
collagen is an integral component of bone tissues, it should be no 
surprise that abnormalities affecting this protein would impact bone 
material quality. At the ultrastructural level, irregularities in collagen 
and mineral geometry as well as abnormalities in mineral composi-
tion have been reported65–70. Studies in mice indicated that the mate-
rial abnormalities in OI have a negative impact on bone material 
properties71–76. A few studies have also used biopsy and osteotomy 
specimens to measure bone material properties in humans with this 
disorder. Some of these studies used nanoindentation, a technique 
in which a diamond-tip indenter is pressed into the polished surface 
of a material (in this case, bone), creating an indent a few microns 
in size. With this test, elastic modulus and hardness—that is, prop-
erties representing the material’s resistance to elastic (recoverable) 
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and plastic (non-recoverable) deformation, respectively—are deter-
mined at the submicrostructural level. Based on nanoindentation, 
slightly higher elastic modulus and hardness were found in chil-
dren with mild (type I) versus severe (type III) OI77, whereas these 
properties were not found to differ between children with severe 
(type III) versus moderately severe (type IV) phenotypes78. However, 
exactly how these properties compare with normal tissues remains 
unclear; one study reported higher elastic modulus and hardness in 
children with severe OI versus controls79, whereas another reported 
the opposite80. Furthermore, bone tissues have a complex hierarchi-
cal structure, which results in properties that differ between length 
scales, and nanoindentation provides only limited insight regard-
ing bone tissue properties at the submicrostructural scale. Another 
limitation with this technique is that it does not measure strength, 
a property representing the ability of a material to carry stress 
without breaking or sustaining damage.
Recent studies have measured cortical bone material properties, 
including strength, at a larger scale by using surgical bone specimens 
from long bone diaphyses of children with OI55,56,81. In these stud-
ies, small osteotomy specimens were machined into parallelepiped- 
shaped specimens and loaded to failure in either bending55,81 or 
compression56. Bone material strength was confirmed to be lower 
than normal in these children, and this property was found to be 
negatively related to an abnormally elevated intracortical porosity. 
These findings suggest that increased cortical porosity contributes 
to increased risk of long bone fractures in OI.
Bone deformity
In addition to decreased bone mass and reduced bone material qual-
ity (low bone material strength), deformities of the spine and long 
bones are common in OI. For example, children with severe OI 
often exhibit anterolateral bowing of the femur and anterior bowing 
of the tibia7,47. Increased curvature in long bones leads to an increase 
in maximum stresses within the bone shaft82. The increased stresses 
attributed to bone deformities in OI can further contribute to the risk 
of bone fracture.
Fracture prediction based on mechanical models
Mechanical modeling through the use of FE analysis is a well-
established technique that allows detailed analysis of composite 
structures under a variety of load conditions. In the field of ortho-
pedic biomechanics, FE modeling is frequently used to examine 
the responses of bone to loading83–86. Patient-specific FE models 
have been effective for bone strain and fracture strength assess-
ment, and as recently as 2009 Fritz et al. applied these models 
to predict fractures in OI87,88. A femoral model including muscle 
forces was analyzed during all seven phases of the gait cycle and 
geometrically matched to bone anatomy with x-rays. The most cur-
rent work includes advanced meshing techniques for improved geo-
metric biofidelity and updated mechanical property data55. Other 
FE models for assessing OI bones have also been reported. Orwoll 
et al. used FE modeling to estimate vertebral strength in a study of 
the effects of teriparatide treatment in adults with OI89. Caouette 
et al. developed an FE model to assess fracture risk at the tibia in 
children with OI90. This tibia model examined fracture risk during 
two-legged hopping, lateral loading, and torsional loading. Future 
applications of FE modeling may prove invaluable for better quan-
tification of fracture risk in OI. These models could help identify 
activities that pose greater risk of fracture and, through appropriate 
controls, may enable persons with OI to participate safely and more 
fully in a greater spectrum of daily and recreational activities.
Management
Physical therapy
The goals of the treatment in OI are to decrease pain and fractures 
and to maximize mobility. Physical therapy/rehabilitation91 is par-
ticularly important in children to improve weight bearing and pre-
vent fractures as well as to increase strength and mobility during 
fracture recovery. Some children may require wheelchairs or walk-
ing aids. Occupational therapy may be needed to help with daily 
living activities.
Pharmacologic therapy
Bisphosphonates
Bisphosphonates (BPs) are non-hydrolysable synthetic analogs of 
pyrophosphate92. BPs adhere to mineralized surfaces, inhibit oste-
oclastic bone resorption, and have very long skeletal half-lives92. 
Intravenous BPs are currently the primary treatment of children 
with moderate to severe OI. BPs increase BMD and size in chil-
dren with OI49. BPs do not appear to impair bone formation that 
increases cortical width in children with OI93. Observational studies 
suggest decreased fractures94,95, decreased bone pain, and improved 
vertebral shape94,95. Ability to perform activities of daily living may 
also be improved. However, it has been difficult to confirm all of 
these benefits in randomized trials, and the optimal duration of BP 
treatment is unknown.
In a study of children with predominantly mild OI, oral risedro-
nate increased BMD and appeared to decrease clinical fractures96. 
Atypical fractures have been reported in children with OI treated 
with bisphosphonates97,98; however, osteneocrosis of the jaw does 
not appear to be a major problem in children with OI treated with 
BPs99–101. Several studies have been done on the use of intravenous 
or oral BPs in adults with OI. Although BMD increases have been 
reported during these treatments, fracture data are equivocal102–106. 
A Cochrane review found increased BMD in patients with OI 
treated with BPs but did not find definitive evidence of fracture 
reduction107. Furthermore, a recent meta-analysis of placebo- 
controlled trials suggested that the effects of BPs for fracture pre-
vention in OI were inconclusive108.
Growth hormone
Growth hormone has anabolic effects on bone. A 1-year rand-
omized trial of the BP, neridronate, with or without growth hormone 
showed greater increase in BMD and growth velocity with growth 
hormone, but there was no fracture benefit of growth hormone109.
Teriparatide
Teriparatide (PTH1-34) is an anabolic agent that stimulates bone 
formation (and ultimately bone resorption). This drug decreases 
vertebral and non-vertebral fractures in post-menopausal women 
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with osteoporosis110. Observational data in adults with OI suggest 
increased BMD with teriparatide107,111. Recently, a randomized trial 
of teriparatide in adults with OI showed increased BMD as well as 
increased vertebral strength estimated by FE analysis91. The ben-
efits appeared to occur in mild (type I) OI but not in more severe OI 
(types III and IV).
Denosumab
Denosumab is a monoclonal antibody to receptor activator of 
nuclear factor kappa B ligand that decreases bone resorption, 
increases bone density, and reduces fractures in women with post-
menopausal osteoporosis112. This drug may represent a future ther-
apy in OI. In a study of four children with type VI OI, increased 
BMD and mobility and improved vertebral shape were reported 
after denosumab treatment, and the outcomes of this study indi-
cated that this treatment appears to be safe113. There is also a report 
of denosumab use in two children with OI caused by COL1A1/A2 
mutations114. As with BPs, “zebra lines” were present, suggesting 
continued longitudinal growth114. Denosumab has been reported to 
cause hypophosphatemia, hypocalcemia, and secondary hyperpar-
athyroidism in a child with fibrous dysplasia of bone115. There was 
rebound hypercalcemia after stopping denosumab115.
Possible future therapies
Sclerostin is an inhibitor of the LRP5/WnT system that decreases 
bone formation. Antibodies to sclerostin are in clinical trials for 
treatment of osteoporosis with the goal to increase bone density116. 
Sclerostin antibody appeared to be effective in a mouse model of 
moderately severe OI117,118 but less so in a mouse model of more 
severe OI119. TGFβ is secreted by osteoblasts and increases osteo-
clastic bone resorption120. Excessive TGFβ signaling may be impor-
tant in some forms of OI, and anti-TGFβ therapy represents an 
interesting prospect for the future treatment of OI120.
Cell-based therapy, such as bone marrow121 or mesenchymal stem 
cell122–124 transplantation, has also been investigated and may have 
promise; but these could also have significant risks. Gene therapy 
with allele-specific silencing may represent a future therapy125.
Summary
Although most cases of OI are caused by COL1A1/A2 mutations, 
many new genetic causes have been identified in recent years. Some 
of these genes are related to the processing of type I collagen. Fur-
thermore, we have greater understanding of the biomechanics of OI 
bone, including material properties, muscle and gait load effects, 
and fracture strength assessment. Biomechanical models could help 
identify activities that pose greater risk of fracture and, through 
appropriate controls, may enable persons with OI to participate 
safely and more fully in a greater spectrum of activities. Physical 
therapy is an important part of the management of these patients. 
Intravenous BPs are commonly used in children with moderate to 
severe OI. Some of the benefits seen in observational studies have 
been hard to prove in controlled studies. Treatment of adults with OI 
is less well studied. BPs and teriparatide appear to increase BMD, 
but fracture data are lacking. Teriparatide appears to increase bone 
strength as estimated by FE analysis in adults with mild OI. Other 
promising treatments for OI are under investigation.
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I have noted a few issues in this article:
On page 2, in the section headed "Genes and classification", gene symbols (  and ) COLIA1 COL1A2
are inappropriately used to designate the component protein chains of type I collagen. Gene
symbols and protein product names should not be used interchangeably. The protein chains are
α1(I) and α2(I) respectively.
In Table 1, the gene symbols for the mutant genes leading to OI types I, II, III and IV are incorrect.
They should be  and , not  and .COL1A1 COL1A2 COL1A1 COLA2
In Table 1, the gene symbol for the gene encoding the protein prolyl-3 hydroxylase is , not P3H1
. The gene symbol for this gene was changed to  in December 2014.LEPRE1 P3H1
Table 1 continues to propagate the notion that there are very many OI types when, in reality, there
are really only five true types which can be clearly distinguished clinically (types I to V). The problem
has been caused by several new OI types being created to correspond to newly discovered genes
which harbour OI-causing sequence variants. This has only served to confuse matters and is
discussed at length by Van Dijk and Sillence (2014) (
).http://www.ncbi.nlm.nih.gov/pubmed/24715559
It is perhaps unsurprising that the article gives emphasis to pharmacological interventions for OI,
given that one of the authors is employed by Alexion Pharmaceuticals, but it is improper to ignore
surgical interventions such as rodding of long bones and mesenchymal stem cell therapy.
There is no mention in the article of the fact that there is a comprehensive database of gene variants
leading to OI: .https://oi.gene.le.ac.uk/
The list of OI genes is incomplete in Table 1. A comprehensive list of genes may be found at 
.https://oi.gene.le.ac.uk/status.php
 I declare that I curate the database of OI gene variants which in mentioned inCompeting Interests:
comment 6.
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